TriangleNCT03168438 · OUTCOME
Duration of Response
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- Full Range
- Time frame
- Up to 108 weeks
What was measured
Duration of response is defined as the interval between the initial date of the confirmed response (sCR, CR, VGPR, or PR) and the initial assesment date of confirmed progressive disease or death among participants with a confirmed response per IMWG (2016).
Analysis population: Modified ITT Population. Only those participants with a confirmed response per IMWG 2016 were analyzed.
Groups in this outcome
GSK3377794
Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single intravenous (IV) infusion of GSK3377794.
GSK3377794+Pembrolizumab
Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single IV infusion of GSK3377794 in combination with pembrolizumab 200 milligrams (mg) administered as an IV infusion every 3 weeks up to Week 108.
| Group | Source count |
|---|---|
| GSK3377794 | 1 |
| GSK3377794+Pembrolizumab | 2 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| GSK3377794 | 2.1 | Not reported | NA | NA | Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual duration of response for this single participant. |
| GSK3377794+Pembrolizumab | 2.1 | Not reported | 2.1 | 2.1 | Not reported |
Complete source fields
- classes
- categories
- measurements
- comment
- Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual duration of response for this single participant.
- group Id
- OG000
- lower Limit
- NA
- upper Limit
- NA
- value
- 2.1
- group Id
- OG001
- lower Limit
- 2.1
- upper Limit
- 2.1
- value
- 2.1
- denoms
- counts
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 2
- units
- Participants
- description
- Duration of response is defined as the interval between the initial date of the confirmed response (sCR, CR, VGPR, or PR) and the initial assesment date of confirmed progressive disease or death among participants with a confirmed response per IMWG (2016).
- dispersion Type
- Full Range
- groups
- description
- Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single intravenous (IV) infusion of GSK3377794.
- id
- OG000
- title
- GSK3377794
- description
- Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single IV infusion of GSK3377794 in combination with pembrolizumab 200 milligrams (mg) administered as an IV infusion every 3 weeks up to Week 108.
- id
- OG001
- title
- GSK3377794+Pembrolizumab
- param Type
- MEDIAN
- population Description
- Modified ITT Population. Only those participants with a confirmed response per IMWG 2016 were analyzed.
- reporting Status
- POSTED
- time Frame
- Up to 108 weeks
- title
- Duration of Response
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice